Globeflex Capital L P Buys 104,321 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Globeflex Capital L P lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 324.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 136,505 shares of the company’s stock after purchasing an additional 104,321 shares during the period. Globeflex Capital L P’s holdings in Amneal Pharmaceuticals were worth $1,720,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Comerica Bank lifted its stake in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the period. Spire Wealth Management lifted its stake in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the period. Focus Partners Wealth purchased a new stake in Amneal Pharmaceuticals in the third quarter worth about $42,000. Advisory Services Network LLC purchased a new stake in Amneal Pharmaceuticals in the third quarter worth about $50,000. Finally, Strs Ohio purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth about $52,000. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMRX. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.17.

Amneal Pharmaceuticals Stock Up 5.0%

NASDAQ:AMRX opened at $13.52 on Friday. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.07 and a 52 week high of $15.42. The firm has a 50 day moving average of $12.70 and a 200 day moving average of $12.96. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of 35.58 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The company had revenue of $722.52 million during the quarter. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Insider Buying and Selling

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 17.30% of the stock is owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.